The added value of PSMA PET/MR radiomics for prostate cancer staging

Standard

The added value of PSMA PET/MR radiomics for prostate cancer staging. / Solari, Esteban Lucas; Gafita, Andrei; Schachoff, Sylvia; Bogdanović, Borjana; Villagrán Asiares, Alberto; Amiel, Thomas; Hui, Wang; Rauscher, Isabel; Visvikis, Dimitris; Maurer, Tobias; Schwamborn, Kristina; Mustafa, Mona; Weber, Wolfgang; Navab, Nassir; Eiber, Matthias; Hatt, Mathieu; Nekolla, Stephan G.

In: EUR J NUCL MED MOL I, Vol. 49, No. 2, 01.2022, p. 527-538.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Solari, EL, Gafita, A, Schachoff, S, Bogdanović, B, Villagrán Asiares, A, Amiel, T, Hui, W, Rauscher, I, Visvikis, D, Maurer, T, Schwamborn, K, Mustafa, M, Weber, W, Navab, N, Eiber, M, Hatt, M & Nekolla, SG 2022, 'The added value of PSMA PET/MR radiomics for prostate cancer staging', EUR J NUCL MED MOL I, vol. 49, no. 2, pp. 527-538. https://doi.org/10.1007/s00259-021-05430-z

APA

Solari, E. L., Gafita, A., Schachoff, S., Bogdanović, B., Villagrán Asiares, A., Amiel, T., Hui, W., Rauscher, I., Visvikis, D., Maurer, T., Schwamborn, K., Mustafa, M., Weber, W., Navab, N., Eiber, M., Hatt, M., & Nekolla, S. G. (2022). The added value of PSMA PET/MR radiomics for prostate cancer staging. EUR J NUCL MED MOL I, 49(2), 527-538. https://doi.org/10.1007/s00259-021-05430-z

Vancouver

Solari EL, Gafita A, Schachoff S, Bogdanović B, Villagrán Asiares A, Amiel T et al. The added value of PSMA PET/MR radiomics for prostate cancer staging. EUR J NUCL MED MOL I. 2022 Jan;49(2):527-538. https://doi.org/10.1007/s00259-021-05430-z

Bibtex

@article{7c2441cd341142cdb661c98d9509566d,
title = "The added value of PSMA PET/MR radiomics for prostate cancer staging",
abstract = "PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients.METHODS: Patients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1-3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student's t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS).RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS.CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics.",
author = "Solari, {Esteban Lucas} and Andrei Gafita and Sylvia Schachoff and Borjana Bogdanovi{\'c} and {Villagr{\'a}n Asiares}, Alberto and Thomas Amiel and Wang Hui and Isabel Rauscher and Dimitris Visvikis and Tobias Maurer and Kristina Schwamborn and Mona Mustafa and Wolfgang Weber and Nassir Navab and Matthias Eiber and Mathieu Hatt and Nekolla, {Stephan G}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = jan,
doi = "10.1007/s00259-021-05430-z",
language = "English",
volume = "49",
pages = "527--538",
journal = "EUR J NUCL MED MOL I",
issn = "1619-7070",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - The added value of PSMA PET/MR radiomics for prostate cancer staging

AU - Solari, Esteban Lucas

AU - Gafita, Andrei

AU - Schachoff, Sylvia

AU - Bogdanović, Borjana

AU - Villagrán Asiares, Alberto

AU - Amiel, Thomas

AU - Hui, Wang

AU - Rauscher, Isabel

AU - Visvikis, Dimitris

AU - Maurer, Tobias

AU - Schwamborn, Kristina

AU - Mustafa, Mona

AU - Weber, Wolfgang

AU - Navab, Nassir

AU - Eiber, Matthias

AU - Hatt, Mathieu

AU - Nekolla, Stephan G

N1 - © 2021. The Author(s).

PY - 2022/1

Y1 - 2022/1

N2 - PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients.METHODS: Patients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1-3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student's t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS).RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS.CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics.

AB - PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients.METHODS: Patients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1-3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student's t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS).RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS.CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics.

U2 - 10.1007/s00259-021-05430-z

DO - 10.1007/s00259-021-05430-z

M3 - SCORING: Journal article

C2 - 34255130

VL - 49

SP - 527

EP - 538

JO - EUR J NUCL MED MOL I

JF - EUR J NUCL MED MOL I

SN - 1619-7070

IS - 2

ER -